Medical Developments International Limited · ASX:MVP
Medical Developments International — Shareholder Meeting (November 2026)
23 slides from Medical Developments International's shareholder meeting presentation, Nov 12, 2026
Slide 1: FY26 Annual General Meeting
For personal use only ASX:MVP FY26 ANNUAL GENERAL MEETING 12 November 2026 1
Slide 2: Important notice and disclaimer
Important notice and disclaimer For personal use only This presentation contains summary information about Medical Developments International Limited (ACN 106340667) and its related bodies corporate (together, MVP) and MVP’s activities as at the date of this presentation. It is information given in
Slide 3: Important notice and disclaimer
Important notice and disclaimer For personal use only Factors that could cause actual results to differ materially include: • the success of research and development activities (including clinical trials); • decisions by regulatory authorities regarding approval of our products as well as their deci
Slide 4: Mark Fladrich, Company Chair
For personal use only Mark Fladrich Company Chair 4
Slide 5: Your Board
Your Board For personal use only Mark Fladrich Russell Basser Paul Townsend Christine Emmanuel- Leon Hoare Company Chair Independent Non-executive Independent Non-executive Donnelly Independent Non-executive Director Director Independent Non-executive Director Director 5
Slide 6: How to ask a question
How to ask a question For personal use only To ask a written question select the Q & A icon Select the topic your question relates to from the drop-down list Type your question in the text box and press the send icon To ask a verbal question follow the instructions below the broadcast window. 6
Slide 7: How to vote
How to vote For personal use only When the poll is open, select the vote icon at the top of the screen To vote, select either For, Against or Abstain You will see a vote confirmation To change or cancel your vote “click here to change your vote” at any time until the poll is closed 7
Slide 8: Solid financial performance in FY26
For personal use only Solid financial performance in FY26 8
Slide 9: Anita James, Interim CEO
For personal use only Anita James Interim CEO 9
Slide 10: FY26 Highlights
FY26 Highlights Solid financial performance, Penthrox® volume growth, key strategy milestones achieved FY26 Highlights For personal use only Solid financial performance, Penthrox® volume growth, key strategy milestones achieved Solid financial performance with strong cashflow generation 1 Group reve
Slide 11: Priorities for FY27
Priorities for FY27 Unlock value from the paediatric indication and accelerate Penthrox® expansion into high-growth markets and segments Priorities for FY27 For personal use only Unlock value from the paediatric indication and accelerate Penthrox® expansion into high-growth markets and segments 1 2
Slide 12: FY27 Outlook
FY27 Outlook FY27 Outlook For personal use only Solid financial performance and progress of Strategy • Solid cashflow generation FY26 • Penthrox® volume growth in all regions • Penthrox® paediatric label approved and launched in UK and European markets • Health economic study completed demonstrating
Slide 13: Questions
For personal use only 13 Questions
Slide 14: Formal Business
For personal use only 14 Formal Business
Slide 15: Resolution: Remuneration Report
Resolution 1 For personal use only “That the Remuneration Report for the year ended 30 June 2026 as set out in the Company’s Annual Report for the year ended 30 June 2026 be adopted.” 15
Slide 16: Resolution Proxy results
Resolution 1 Proxy results For personal use only For Against Open Abstain No. Of Shares 23,372,994 1,384,847 209,407 128,989 % of Total 93.61 5.55 0.84 NA Proxies 16
Slide 17: Resolution: Re-election of Dr Russell Basser
Resolution 2 For personal use only “That pursuant to the Company’s Constitution and for all other purposes, the members of the Company approve the re-election of Dr Russell Basser as a Non- Executive Director of the Company, who pursuant to clause 12.4 of the Company’s Constitution is retiring and b
Slide 18: Resolution Proxy results
Resolution 2 Proxy results For personal use only For Against Open Abstain No. Of Shares 24,261,066 822,773 209,658 352,387 % of Total 95.91 3.26 0.83 NA Proxies 18
Slide 19: Resolution: Re-election of Mr Paul Townsend
Resolution 3 For personal use only “That pursuant to the Company’s Constitution and for all other purposes, the members of the Company approve the re-election of Mr Paul Townsend as a Non- Executive Director of the Company, who pursuant to clause 12.4 of the Company’s Constitution is retiring and be
Slide 20: Resolution Proxy results
Resolution 3 Proxy results For personal use only For Against Open Abstain No. Of Shares 24,252,725 831,114 209,658 352,387 % of Total 95.88 3.29 0.83 NA Proxies 20
Slide 21: Resolution: Rights Plan Rules
Resolution 4 For personal use only “That the shareholders approve the Company’s new Rights Plan Rules for the purposes of ASX Listing Rule 7.2 Exception 13(b), sections 200B, 200E and 259B(2) of the Corporations Act and for all other purposes, as laid before the meeting, a copy of which is available
Slide 22: Resolution Proxy results
Resolution 4 Proxy results For personal use only For Against Open Abstain No. Of Shares 23,052,313 1,686,037 209,658 148,229 % of Total 92.40 6.76 0.84 NA Proxies 22
Slide 23: Conclusion
For personal use only 23 Conclusion
Medical Developments International — Shareholder Meeting (November 2026) on 6ix